Rachid Rafia
MSc
School of Health and Related Research
Health Economic Consultant
+44 114 222 0739
Full contact details
School of Health and Related Research
213
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
- Profile
-
I joined ScHARR in February 2008, having completed a MSc in management of health care and health economics at the University Paris 1 Pantheon Sorbonne. I have worked as a health economic consultant and worked mainly on infectious diseases. Since joining ScHARR, I have gained experienced in modelling diseases such as Friedreich's ataxia, multiple sclerosis, soft tissue sarcoma, psoriatic arthritis, breast cancer, deep vein thrombosis and follicular lymphoma…etc.
I was also involved in the modelling of the impact of reducing the blood alcohol concentration level in the England and Wales, extending breast cancer screening to older women and using GEP and IHC tests to help chemotherapy decision making in the UK.I am currently working on modelling breast cancer screening in the elderly.
I have experience in model validation, critical appraisal and model development and have been involved in the Single Technology Appraisal (STA) process in terms of reviewing and critically appraising manufacturer’s submission for NICE (ovarian cancer, soft tissue sarcoma, deep vein thrombosis). I have also been involved in two Multiple Technology Appraisal (MTA) and a NICE diagnostic review (breast cancer diagnostics).
- Research interests
-
My research interests are:
- Health economics and economic evaluation
- Health economic modelling for decision making
I am particularly interested in the economic evaluation of oncology treatments and infectious diseases
Current projects
I am currently working on the following projects:
- Evaluating the cost-effectiveness of interventions looking at increasing hepatitis B vaccination uptake among injecting drug users
- Modelling the cost-effectiveness of treatment in Myelofibrosis
- Cost-benefit analysis of intervention for occupational asthma and rhinitis among bakery workers
- provide guidance for the treatment of frailer older women with oestrogen receptor +ve breast cancer to ensure optimal treatment with either surgery (+adjuvant endocrine therapy) or primary endocrine therapy (PET).
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. Addiction, 111(9), 1616-1627. View this article in WRRO
- Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(12), 1241-1253. View this article in WRRO
- Modeling the Cost-Effectiveness of Alternative Upper Age Limits for Breast Cancer Screening in England and Wales. Value in Health, 19(4), 404-412.
- Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.. Health Technol Assess, 17(44), 1-302. View this article in WRRO
- Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.. Pharmacoeconomics, 31(6), 471-478.
- Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.. Health Technol Assess, 16(37), 1-iv.
- Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.. Bone Marrow Transplant, 45(6), 1014-1021.
- Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective.. Expert Rev Pharmacoecon Outcomes Res, 9(5), 423-433.
All publications
Journal articles
- Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 23(30). View this article in WRRO
- Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. Pharmacoeconomics. View this article in WRRO
- Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1143-1151. View this article in WRRO
- Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimens in breast cancer management: a systematic review.. International Journal of Technology Assessment in Health Care, 33(1), 32-45. View this article in WRRO
- Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(5), 537-547. View this article in WRRO
- The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation. BMC Health Services Research, 17(1), 78-78. View this article in WRRO
- An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. Addiction, 111(9), 1616-1627. View this article in WRRO
- Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(12), 1241-1253. View this article in WRRO
- Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation.. Health Technology Assessment, 20(46), 1-246. View this article in WRRO
- Modeling the Cost-Effectiveness of Alternative Upper Age Limits for Breast Cancer Screening in England and Wales. Value in Health, 19(4), 404-412.
- Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(5), 537-547.
- Developing policy analytics for public health strategy and decisions—the Sheffield alcohol policy model framework. Annals of Operations Research, 236(1), 149-176. View this article in WRRO
- The Sheffield Alcohol Policy Model - A Mathematical Description. Health Economics, 24(10), 1368-1388. View this article in WRRO
- Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.. Health Technol Assess, 17(44), 1-302. View this article in WRRO
- Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.. Pharmacoeconomics, 31(6), 471-478.
- Modelling the cost-effectiveness of alcohol screening and brief interventions in primary care in England.. Alcohol Alcohol, 48(2), 180-188.
- Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.. Health Technol Assess, 16(37), 1-iv.
- Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?. Eur J Prev Cardiol, 19(3), 474-483.
- Trabectedin for the treatment of relapsed ovarian cancer.. Health Technol Assess, 15 Suppl 1, 69-75.
- Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK.. Rheumatology (Oxford), 49(10), 1949-1956.
- Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.. Health Technol Assess, 14 Suppl 1, 63-67.
- Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model.. Lancet, 375(9723), 1355-1364.
- Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.. Bone Marrow Transplant, 45(6), 1014-1021.
- Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective.. Expert Rev Pharmacoecon Outcomes Res, 9(5), 423-433.
- Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.. Curr Med Res Opin, 24(5), 1473-1483.
- Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium.. J Med Econ, 11(3), 431-448.
Conference proceedings papers
- Does the generic cancer outcome measure eortc qlq-c30 work in myelofibrosis?. Value in Health, Vol. 18(3) (pp A210-A211)
- Exploratory Psychometric Analysis of The Eq-5d In A Myelofibrosis Population. Value in Health, Vol. 18(3) (pp A211-A211)
- Approaches Used to Model the Relationship Between Progression-Free Survival (PFS) / Time-To-Progression (TTP) And Overall Survival (OS) Within Health Economic Models of Cancer Therapies. Value in Health, Vol. 17(7) (pp A557-A557)
- EVALUATING THE COST EFFECTIVENESS OF GENE EXPRESSION PROFILING AND IMMUNOHISTOCHEMISTRY TESTS. VALUE IN HEALTH, Vol. 16(7) (pp A413-A413)
- EVALUATING THE COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA PATIENTS IN THE UK. VALUE IN HEALTH, Vol. 14(7) (pp A445-A445)
Reports
Posters
- An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. Addiction, 111(9), 1616-1627. View this article in WRRO
- Teaching interests
-
I also teach on the distance learning Master in International Health Technology Assessment (iHTA) and supervise a master dissertation for the HEDM course.
My teaching interests are:
- Health economics and economic evaluation
- Health economic modelling for decision making